SCHEMBL2707336

SCHEMBL2707336

O=C(O)c1ccc(O)c(=O)o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.47
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
KLKB1 P03952 1/20 0.41
CTSB P07858 1/20 0.41
MMP9 P14780 1/20 0.41
DNMT1 P26358 1/20 0.41
DNMT3B Q9UBC3 1/20 0.41
DNMT3L Q9UJW3 1/20 0.41
DNMT3A Q9Y6K1 1/20 0.41
POLB P06746 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
AKR1B1 P15121 1/20 0.38
MAOA P21397 1/20 0.38
KDM4E B2RXH2 1/20 0.38
RGS12 O14924 1/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11904537 0.77 TDP1 (0.61) TDP1ALDH1A1HPGDPOLBMEN1
SCHEMBL38726 0.77 TDP1 (0.61) TDP1ALDH1A1HPGDPOLBMEN1
SCHEMBL31064999 0.75 HTT (0.55) ALDH1A1HPGDPOLBMEN1KMT2A
Bromide SCHEMBL20513084 0.75 TDP1 (0.58) TDP1ALDH1A1HPGDPOLBMEN1
Fluoride SCHEMBL21331933 0.75 TDP1 (0.58) TDP1ALDH1A1HPGDPOLBMEN1
SCHEMBL23727166 0.75 TDP1 (0.58) TDP1ALDH1A1HPGDPOLBMEN1
SCHEMBL18074260 0.75 TDP1 (0.58) TDP1ALDH1A1HPGDPOLBMEN1
Fluoride SCHEMBL20513066 0.75 TDP1 (0.58) TDP1ALDH1A1HPGDPOLBMEN1
Ammonia Solution, Strong SCHEMBL16240294 0.75 TDP1 (0.58) TDP1ALDH1A1HPGDPOLBMEN1
SCHEMBL18074258 0.75 TDP1 (0.58) TDP1ALDH1A1HPGDPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022234466-A1 NEW PROCESS FOR PREPARING 3-HYDROXY-2-PYRONE POLITECNICO DI MILANO (IT) 2022-11-10 WO claimed
EP-4651944-A1 INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2025-11-26 EP disclosed
EP-4652164-A1 INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2025-11-26 EP disclosed
EP-4638446-A1 THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2025-10-29 EP disclosed
EP-4554928-A1 ELASTOMER COMPOSITIONS COMPRISING AT LEAST ONE SP2 HYBRIDIZED CARBON ALLOTROPE AND A 2,5-DISUBSTITUTED PYRROLE DERIVATIVE Pirelli Tyre S.p.A. (IT) 2025-05-21 EP disclosed
US-12258275-B2 Elastomer compositions comprising an adduct between an SP2 hybridized carbon allotrope and a dicarboxylic acid derivative PIRELLI TYRE S.P.A. (IT) 2025-03-25 US disclosed
CN-119562943-A Comprising at least one sp2Elastomeric compositions of hybrid carbon allotrope and 2, 5-disubstituted pyrrole derivatives 倍耐力轮胎股份公司 2025-03-04 CN disclosed
US-20250002487-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2025-01-02 US disclosed
WO-2024233812-A1 INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2024-11-14 WO disclosed
WO-2024233767-A1 INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2024-11-14 WO disclosed
US-8263629-B2 Substituted aminobutyric derivatives as neprilysin inhibitors NOVARTIS AG (CH) 2012-09-11 US disclosed
US-8263629-B2 Substituted aminobutyric derivatives as neprilysin inhibitors NOVARTIS AG (CH) 2012-09-11 US disclosed
US-8263629-B2 Substituted aminobutyric derivatives as neprilysin inhibitors NOVARTIS AG (CH) 2012-09-11 US disclosed
WO-2012075053-A2 LIGNIN OXIDATION AND PRODUCTS THEREOF STRATEGIC ENZYME APPLICATIONS, INC. (US) 2012-06-07 WO disclosed
EP-2435402-A2 SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS Novartis AG (CH) 2012-04-04 EP disclosed
WO-2010136474-A2 SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS NOVARTIS AG (CH) 2010-12-02 WO disclosed
WO-2010136474-A2 SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS NOVARTIS AG (CH) 2010-12-02 WO disclosed
US-20100305145-A1 Substituted Aminobutyric Derivatives as Neprilysin Inhibitors NOVARTIS AG (CH) 2010-12-02 US disclosed
US-20100305145-A1 Substituted Aminobutyric Derivatives as Neprilysin Inhibitors NOVARTIS AG (CH) 2010-12-02 US disclosed
US-20100305145-A1 Substituted Aminobutyric Derivatives as Neprilysin Inhibitors NOVARTIS AG (CH) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002487-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF CGAS, TDP1, CYP11B2 TDP1 2/4885ALDH1A1 987/4885HPGD 516/4885
US-20100305145-A1 Substituted Aminobutyric Derivatives as Neprilysin Inhibitors MME, GABRB1, GABRE TDP1 1584/4885ALDH1A1 1125/4885HPGD 2249/4885
US-12258275-B2 Elastomer compositions comprising an adduct between an SP2 hybridized carbon allotrope and a dicarboxylic acid derivative FUT6, FUT5, GNE TDP1 4178/4885ALDH1A1 448/4885HPGD 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.